Edity Therapeutics is a cutting-edge brand that specializes in cellular re-programming utilizing the immune system. Their innovative approach involves using immune cells to deliver therapeutic proteins directly to the cytoplasm of diseased cells, resulting in improved patient health and longevity. Unlike existing therapeutic approaches that are limited by tissue tropism, toxicity, or payload size, Edity's technology is capable of introducing functional proteins into cells and targeting specific tissues.

By harnessing immune cells' ability for deep tissue penetration and intracellular protein delivery, Edity is able to offer a new universe of targets for treatment that have not previously been translated to the clinic. Their plug and play technology builds on clinical-grade technologies and is compatible with allogeneic approaches, working effectively with T-cells, NK cells, CAR, TCR, or similar modalities for homing and activation. Edity Therapeutics aims to create new modalities for intracellular therapy, delivering proteins to cells anywhere in the body.

With a vision to transform the immune response and reprogram cells from the inside out, Edity is actively developing programs for various indications, including oncology and genetic diseases, as well as regeneration and longevity